Overview
This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.
Eligibility
Inclusion Criteria:
- Adults aged 19 years or older
- Diagnosed with early or advanced gastric, lung, breast, or colon cancer
- Starting first-cycle chemotherapy with a new anticancer agent
- Able to use a smartphone without difficulty
- Willing to provide informed consent to participate in the study
Exclusion Criteria:
- Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons
- Individuals who cannot read, write, or understand Korean
- Other individuals deemed inappropriate for participation by the investigators